Finally, our analysis of PFI data demonstrated that elevated RBFOX2 levels were correlated with shorter PFI in ACC, BLCA, BRCA, CESC, HNSC, LUAD, and UVM patients (Supplementary Figure S4). Here, RBFOX2 is linked to bladder transitional cell carcinoma.